Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pages: 76 Published: May 30, 2022 Report Code: GDHC064CL

Neuroendocrine tumors pipeline drugs market report includes an assessment of the disease epidemiology, the leading marketed products with sales forecasts, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and likelihood of approval (LoA) for neuroendocrine tumors (NET).  The report also analyzes the clinical and commercial landscapes of NET, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Neuroendocrine neoplasms (NENs) are a group of rare, heterogeneous tumors that can develop sporadically in many different organs of the body and arise from specialized cells of the nervous and endocrine system called the neuroendocrine cells.

Which are the key regions in the Neuroendocrine tumors pipeline drugs market?

The key regions in the Neuroendocrine tumors pipeline drugs market are Asia-Pacific, Europe, Middle East & Africa, North America, South & Central America. Single-country trials for NET were active mostly in the northern hemisphere, with the highest number of trials conducted in North America.

Neuroendocrine tumors pipeline drugs market, by regions

Neuroendocrine tumors pipeline drugs market, by regions

For more region insights, download a free report sample

Which are the key stages of development in the Neuroendocrine tumors pipeline drugs market?

The key stages of development in the Neuroendocrine tumors pipeline drugs market are pre-registration, phase I, phase II, phase III, preclinical, discovery, and IND/CTA filed. Phase II has the highest share in the Neuroendocrine tumors pipeline drugs market.

Neuroendocrine tumors pipeline drugs market, by development stages

Neuroendocrine tumors pipeline drugs market, by development stages

For more development stage insights, download a free report sample

Which are the key MoA in the Neuroendocrine tumors pipeline drugs market?

The key MoA in the Neuroendocrine tumors pipeline drugs market are enzyme inhibitor, receptor antagonist, receptor agonist, cytotoxic, protein and peptide inhibitor, receptor inhibitor, protein and peptide activator, transporter activator, transporter inhibitor and others. Enzyme inhibitor has the highest share in the Neuroendocrine tumors pipeline drugs market.

Neuroendocrine tumors pipeline drugs market, by MoA

Neuroendocrine tumors pipeline drugs market, by MoA

For more MoA insights, download a free report sample

Which are the key RoA in the Neuroendocrine tumors pipeline drugs market?

The key RoA in the Neuroendocrine tumors pipeline drugs market are injection, oral, topical, and inhalation. Injection has the highest share in the Neuroendocrine tumors pipeline drugs market.

Neuroendocrine tumors pipeline drugs market, by RoA

Neuroendocrine tumors pipeline drugs market, by RoA

For more RoA insights, download a free report sample

Which are the key molecule types in the Neuroendocrine tumors pipeline drugs market?

The key molecule types in the Neuroendocrine tumors pipeline drugs market are biologic, small molecule, oligonucleotide. Biologic has the highest share in the Neuroendocrine tumors pipeline drugs market.

Neuroendocrine tumors pipeline drugs market, by molecule types

Neuroendocrine tumors pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key sponsors in the Neuroendocrine tumors pipeline drugs market?

The key sponsors in the Neuroendocrine tumors pipeline drugs market are National Cancer Institute US, Hutchison Medipharma Ltd, Pecking University, Novartis AG, F. Hoffman-La Roche Ltd, Ipsen SA, and others. The National Cancer Institute US has sponsored the highest number of clinical trials.

Neuroendocrine tumors pipeline drugs market, by sponsors

Neuroendocrine tumors pipeline drugs market, by sponsors

To know more about sponsors, download a free report sample

Market report overview

Key Regions Asia-Pacific, Europe, Middle East & Africa, North America, South & Central America
Key MoA Enzyme Inhibitor, Receptor Antagonist, Receptor Agonist, Cytotoxic, Protein And Peptide Inhibitor, Receptor Inhibitor, Protein And Peptide Activator, Transporter Activator, Transporter Inhibitor and Others
Key RoA Injection, Oral, Topical, and Inhalation
Key Molecule Types Biologic, Small Molecule, Oligonucleotide
Key Development Stage Pre-Registration, Phase I, Phase II, Phase III, Preclinical, Discovery and IND/CTA Filed
Key sponsors National Cancer Institute US, Hutchison Medipharma Ltd, Pecking University, Novartis AG, F. Hoffman-La Roche Ltd, Ipsen SA, and others

Scope

GlobalData’s Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type and Route of Administration
  • Product Profiles with Sales Forecast
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Neuroendocrine tumors market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Neuroendocrine tumors market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Route of Administration

4.4 Overview by Molecule Type

4.5 Marketed Drugs Profiles and Sales Forecasts

5 Pipeline Drugs Assessment

5.1 Late-stage Pipeline Drugs

5.2 Overview by Development Stage

5.3 Overview by Mechanism of Action

5.4 Overview by Route of Administration

5.5 Overview by Molecule Type

5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

5.7 Therapy Area and Indication-specific PTSR and LoA

6 Clinical Trials Assessment

6.1 Historical Overview

6.2 Overview by Phase

6.3 Overview by Status

6.4 Overview by Phase for Ongoing and Planned Trials

6.5 Trials with Virtual Components

6.6 Geographic Overview

6.7 Single-Country and Multinational Trials by Region

6.8 Top 20 Sponsors with Breakdown by Phase

6.9 Top 20 Sponsors with Breakdown by Status

6.10 Overview by Endpoint Status

6.11 Overview by Race and Ethnicity

6.12 Enrollment Data

6.13 Top 20 countries for Trial Sites

6.14 Top 20 Sites Globally

6.15 Feasibility Analysis – Geographic Overview

6.16 Feasibility Analysis – Benchmark Models

7 Deals Landscape

7.1 Mergers, Acquisitions, and Strategic Alliances by Region

7.2 Recent Mergers, Acquisitions, and Strategic Alliances

8 Commercial Assessment

8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

10.1 Methodology

10.2 Methodology – PTSR and LoA Analysis

10.3 About the Authors

10.4 Contact Us

10.5 Disclaimer

Frequently Asked Questions

Request a Free Sample
$3495

Can be used by individual purchaser only

$10485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.